Uncategorized

GSK ends brain drug alliance with Alector

Clinical setbacks derailed what was once a potentially $2.2 billion deal that marked GSK’s return to neuroscience.

​Read More

Published

on

Clinical setbacks derailed what was once a potentially $2.2 billion deal that marked GSK’s return to neuroscience.

​Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version